Growth characteristics of HCT116 xenografts lacking asparagine synthetase vary according to sex
Document Type
Article
Publication Title
Human genomics
Abstract
BACKGROUND: Sex-related differences in colorectal (CRC) incidence and mortality are well-documented. However, the impact of sex on metabolic pathways that drive cancer growth is not well understood. High expression of asparagine synthetase (ASNS) is associated with inferior survival for female CRC patients only. Here, we used a CRISPR/Cas9 technology to generate HCT116 ASNS and HCT 116 ASNS cancer cell lines. We examine the effects of ASNS deletion on tumor growth and the subsequent rewiring of metabolic pathways in male and female Rag2/IL2RG mice. RESULTS: ASNS loss reduces cancer burden in male and female tumor-bearing mice (40% reduction, q < 0.05), triggers metabolic reprogramming including gluconeogenesis, but confers a survival improvement (30 days median survival, q < 0.05) in female tumor-bearing mice alone. Transcriptomic analyses revealed upregulation of G-protein coupled estrogen receptor (GPER1) in tumors from male and female mice with HCT116 ASNS xenograft. Estradiol activates GPER1 in vitro in the presence of ASNS and suppresses tumor growth. CONCLUSIONS: Our study indicates that inferior survival for female CRC patients with high ASNS may be due to metabolic reprogramming that sustains tumor growth. These findings have translational relevance as ASNS/GPER1 signaling could be a future therapeutic target to improve the survival of female CRC patients.
First Page
67
DOI
10.1186/s40246-024-00635-3
Publication Date
6-17-2024
Recommended Citation
Aladelokun, Oladimeji; Lu, Lingeng; Zheng, Jie; Yan, Hong; Jain, Abhishek; Gibson, Joanna; Khan, Sajid A.; and Johnson, Caroline H., "Growth characteristics of HCT116 xenografts lacking asparagine synthetase vary according to sex" (2024). Surgery. 201.
https://scholar.bridgeporthospital.org/surgery/201
Identifier
38886847 (pubmed); PMC11184737 (pmc); 10.1186/s40246-024-00635-3 (doi); 10.1186/s40246-024-00635-3 (pii)